Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Exact Sciences

Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2022

Upgrades

Benzinga

Would Exact Sciences Acquire Invitae? Unlikely.

Social media is speculating about the idea that Exact Sciences would buy Invitae. Investors should pinch themselves out of the daydream.

The Street

Europe Strikes Down Another Illumina Acquisition

A complicated merger situation for Illumina just got messier.

The Street

From analysis to the latest developments in health,
read the most diverse news in one place.

Exact Sciences: Don't Deem It Guilty by Association

Genetic-testing stocks, especially those championed by asset manager Cathie Wood, have been pummeled. It's important to differentiate.

The Street

Ginkgo Bioworks is Toying With Wall Street

The synthetic biology pioneer has underpromised and over-delivered on biosecurity revenue in 2022. Here's what comes next.

The Street

This Unpopular Move Could Save Invitae

Offloading a recent acquisition could accelerate the path to profitability – or an acquisition.

The Street

5 Headwinds Facing Liquid Biopsies in Colon Cancer Screening

Exact Sciences, maker of Cologuard, won't be dethroned anytime soon.

The Street

Read news from The Economist, FT, and more,
with one subscription

Invitae Goes Full Meme Stock. What's Next?

Shares of the genetic testing company have more than doubled in less than a week. It likely isn't durable.

The Street

Exact Sciences Goes Full Wu-Tang On Wall Street

Cash rules everything around the diagnostics leader, which pledged to prioritize profitable growth.

The Street

Is Cologuard Maker Exact Sciences Underestimating Revenue Guidance?

Exact Sciences has the world's first $1 billion diagnostic test: Cologuard, the colon-cancer-screening system.

The Street

Did a Huge Government Program Just Boost One Major Biotech Stock?

A big change may pave the way for one big name to become an even bigger money maker.

The Street

Next-gen blood tests to detect cancer and other diseases come with questions

The tests can help detect some diseases early but it's still unclear how much they affect whether someone survives a disease.

Axios

Expert Ratings for Exact Sciences

Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings within the last quarter:

Benzinga

Exact Sciences's Return On Capital Employed Insights

According to data from Benzinga Pro, during Q1, Exact Sciences's (NASDAQ:EXAS) reported sales totaled $486.57 million. Despite a 17.98% increase in earnings, the company posted a loss of $180.94 million.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

SVB Leerink Maintains Outperform Rating for Exact Sciences: Here's What You Need To Know

SVB Leerink has decided to maintain its Outperform rating of Exact Sciences (NASDAQ:EXAS) and lower its price target from $130.00 to $95.00. Shares of Exact Sciences are trading up 7.86% over the last 24 hours, at $63.24 per share.

Benzinga

Here's How Much You Would Have Made Owning Exact Sciences Stock In The Last 10 Years

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 10 years by 7.98% on an annualized basis producing an average annual return of 19.54%. Currently, Exact Sciences has a market capitalization of $10.72 billion.

Benzinga

Preview: Exact Sciences's Earnings

Exact Sciences (NASDAQ:EXAS) is set to give its latest quarterly earnings report on Tuesday, 2022-04-26. Here's what investors need to know before the announcement. Analysts estimate that Exact Sciences will report an earnings per share (EPS) of $-1.07.

Benzinga

Analyst Ratings for Exact Sciences

Within the last quarter, Exact Sciences (NASDAQ:EXAS) has observed the following analyst ratings:

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Here's How Much $1000 Invested In Exact Sciences 20 Years Ago Would Be Worth Today

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 20 years by 2.83% on an annualized basis producing an average annual return of 10.04%. Currently, Exact Sciences has a market capitalization of $11.93 billion.

StockNews.com

3 Healthtech Stocks Wall Street Predicts Will Rally More Than 40% or More: GoodRx, 23andMe, and Exact Sciences

The COVID-19 pandemic has accelerated digital adoption in healthcare. And because this trend is attracting massive investments into digital health care, Wall Street analysts expect popular health tech stocks Exact Sciences Corp (EXAS), GoodRx Holdings (GDRX), 23andMe (ME) to rally in price soon. Read on.

Benzinga

$100 Invested In This Stock 5 Years Ago Would Be Worth This Much

Exact Sciences (NASDAQ:EXAS) has outperformed the market over the past 5 years by 12.08% on an annualized basis.

Benzinga

Where Exact Sciences Stands With Analysts

Over the past 3 months, 4 analysts have published their opinion on Exact Sciences (NASDAQ:EXAS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Exact Sciences: Q4 Earnings Insights

Exact Sciences (NASDAQ:EXAS) reported its Q4 earnings results on Tuesday, February 22, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

StockNews.com

3 Large-Cap Healthcare Stocks with More Than 40% Upside, According to Wall Street

The healthcare industry is growing rapidly on increasing demand and continuing advancements in therapies. Furthermore, this year is expected to be a transformative one for the healthcare sector, with a more robust transition to digital health. Given the industry's growth potential, Wall Street analysts see more than 40% potential upside…

1 2 3 4

People

Anne Wojcicki

23 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.